Glypressin (Terlipressin Acetate)

Glypressin is an intravenous formulation containing the active ingredient terlipressin acetate. It is supplied in a prescription‑only format and is marketed within the European Union. As a vasopressin analog, Glypressin acts as a selective V1 receptor agonist, producing vasoconstriction that raises systemic vascular resistance and lowers portal venous pressure. The product is used under medical supervision for specific hepatic and gastrointestinal conditions in clinical practice.

Glypressin is indicated for the management of specific complications associated with advanced liver disease and portal hypertension.

- Control of acute bleeding from esophageal varices in patients with cirrhosis. - Adjunctive therapy for hepatorenal syndrome to improve renal perfusion. - Temporary reduction of portal venous pressure during endoscopic procedures. - Supportive treatment in patients undergoing liver transplantation where portal pressure reduction is required. - Management of refractory hypotension secondary to severe vasodilation in hepatic failure.

The pharmacologic activity of Glypressin may be associated with a range of adverse effects, which are generally categorized by frequency and clinical significance.

Common: - Headache, dizziness, or flushing caused by transient vasoconstriction, usually mild and self‑limiting. - Nausea, abdominal discomfort, or mild diarrhea, often occurring shortly after infusion. - Transient increase in blood pressure or heart rate, typically returning to baseline without intervention.

Serious: - Severe hypertension or hypertensive crisis, potentially requiring immediate medical intervention. - Cardiac arrhythmias, including episodes of tachycardia or bradycardia, which may compromise cardiac output. - Ischemic events such as myocardial infarction or peripheral limb ischemia, presenting with chest pain or limb discoloration. - Acute renal failure or worsening of existing renal impairment, manifested by reduced urine output and rising serum creatinine. - Gastrointestinal ischemia leading to ulceration or perforation, which may cause severe abdominal pain and bleeding.

When prescribing Glypressin, clinicians should evaluate patient-specific factors and monitor for conditions that may increase the risk of adverse outcomes.

- Assess cardiovascular status, especially in patients with uncontrolled hypertension or known coronary artery disease. - Evaluate renal function before initiation and monitor serum creatinine during therapy. - Use caution in patients with a history of peripheral vascular disease or ischemic limb conditions. - Avoid use in individuals with active gastrointestinal bleeding unrelated to varices, as vasoconstriction may worsen ischemia. - Consider the potential for fluid overload; monitor fluid balance and signs of pulmonary edema. - Review pregnancy and lactation status, as safety data are limited.

Glypressin may interact with other medications that affect vascular tone, cardiac function, or renal handling; awareness of these interactions helps minimize risk.

Avoid: - Concomitant use with other vasopressors or potent vasoconstrictors (e.g., norepinephrine, phenylephrine) can cause excessive hypertension. - Co‑administration with phosphodiesterase‑5 inhibitors (e.g., sildenafil) may increase the risk of severe hypotension after vasoconstriction reversal. - Avoid drugs that prolong the QT interval due to additive cardiac effects.

Use with caution: - Beta‑blockers may blunt the desired hemodynamic response; dose adjustments may be required. - Loop diuretics can exacerbate renal hypoperfusion; monitor renal function closely. - Anticoagulants or antiplatelet agents may raise bleeding risk if portal pressure reduction is inadequate; monitor closely.